| Trademark Snap Shot ITU Unit Action (Table presents the data on ITU Unit Action) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 87352574 | FILING DATE | 02/28/2017 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | MICHELI, ANGELA M |
L.O. ASSIGNED | 101 |
PUB INFORMATION |
|||
| RUN DATE | 08/22/2020 | ||
| PUB DATE | 12/26/2017 | ||
| STATUS | 734-FIFTH EXTENSION - GRANTED | ||
| STATUS DATE | 08/21/2020 | ||
| LITERAL MARK ELEMENT | TEVA | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | NO |
| LITERAL MARK ELEMENT | TEVA |
| MARK DRAWING CODE | 3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S) |
| COLOR DRAWING FLAG | YES |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 20-OWNER AT PUBLICATION |
| NAME | Teva Pharmaceutical Industries Limited |
| ADDRESS | Science Based Industries Campus Har Hotzvim Jerusalem, 91010 |
| ENTITY | 99-limited company (ltd.) |
| CITIZENSHIP | Israel |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| COLORS CLAIMED STATEMENT | The color(s) dark green, light green, white and gray is/are claimed as a feature of the mark. |
| DESCRIPTION OF MARK | The mark consists of a light green design that begins at the bottom left hand corner and rises up to the upper right hand corner. This light green continues in a straight light across the top. There are 2 darker green half circles at the bottom right hand corner that when they intersect make a dark green. In the dark green intersection at the bottom right hand corner is the word "teva" in lower case white letters. The "v" in the word "teva" is formed by 2 leaf shapes. The color white also appears in the rectangle created by the gray outlining the entire mark. The entire mark is outlined by a thin gray line. |
| TRANSLATION | The English translation of "TEVA" in the mark is "NATURE". |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 08/22/2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 041 |
| 08/21/2020 | EX5G | S | EXTENSION 5 GRANTED | 040 |
| 08/13/2020 | EXT5 | S | EXTENSION 5 FILED | 039 |
| 08/18/2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | 038 |
| 08/13/2020 | EEXT | I | TEAS EXTENSION RECEIVED | 037 |
| 02/29/2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 036 |
| 02/19/2020 | EX4G | S | EXTENSION 4 GRANTED | 035 |
| 02/19/2020 | EXT4 | S | EXTENSION 4 FILED | 034 |
| 02/19/2020 | EEXT | I | TEAS EXTENSION RECEIVED | 033 |
| 02/19/2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | 032 |
| 08/15/2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 031 |
| 08/13/2019 | EX3G | S | EXTENSION 3 GRANTED | 030 |
| 08/13/2019 | EXT3 | S | EXTENSION 3 FILED | 029 |
| 08/13/2019 | EEXT | I | TEAS EXTENSION RECEIVED | 028 |
| 02/15/2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 027 |
| 02/13/2019 | EX2G | S | EXTENSION 2 GRANTED | 026 |
| 02/13/2019 | EXT2 | S | EXTENSION 2 FILED | 025 |
| 02/13/2019 | EEXT | I | TEAS EXTENSION RECEIVED | 024 |
| 08/15/2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 023 |
| 08/13/2018 | EX1G | S | EXTENSION 1 GRANTED | 022 |
| 08/13/2018 | EXT1 | S | EXTENSION 1 FILED | 021 |
| 08/13/2018 | EEXT | I | TEAS EXTENSION RECEIVED | 020 |
| 02/20/2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 019 |
| 12/26/2017 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 018 |
| 12/26/2017 | PUBO | A | PUBLISHED FOR OPPOSITION | 017 |
| 12/06/2017 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 016 |
| 11/17/2017 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 015 |
| 11/17/2017 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | 014 |
| 11/17/2017 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 013 |
| 11/17/2017 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | 012 |
| 11/17/2017 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | 011 |
| 11/14/2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 010 |
| 11/14/2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 009 |
| 11/14/2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 008 |
| 05/26/2017 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | 007 |
| 05/26/2017 | GPRA | F | PRIORITY ACTION E-MAILED | 006 |
| 05/26/2017 | CPRA | R | PRIORITY ACTION WRITTEN | 005 |
| 05/23/2017 | DOCK | D | ASSIGNED TO EXAMINER | 004 |
| 03/08/2017 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | 003 |
| 03/07/2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
| 03/03/2017 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Laurence Rickles |
| CORRESPONDENCE ADDRESS | Laurence Rickles TEVA PHARMACEUTICALS USA, INC. 4oo Interpace Parkway Parsippany, NJ 07054 |
| DOMESTIC REPRESENTATIVE | NONE |
PRIOR OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Teva Pharmaceutical Industries Limited |
| ADDRESS | Science Based Industries Campus Har Hotzvim, P.O. Box 1142 Jerusalem, 91010 |
| ENTITY | 99-limited company (ltd.) |
| CITIZENSHIP | Israel |